Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3809667 | 0.98 | CA12 (0.42) | CA12CA2CA9CA1CA4 | |
| Benzene SCHEMBL9207756 | 0.95 | CA12 (0.40) | CA12CA2CA9CA1CA4 | |
| Methane SCHEMBL11040703 | 0.89 | CA12 (0.39) | CA12CA2CA9CA1CA4 | |
| Pyridine SCHEMBL11104234 | 0.87 | SLC40A1 (0.36) | CA12CA2CA9CA1CA4 | |
| SCHEMBL7190117 | 0.86 | CA12 (0.43) | CA12CA2CA9CA1CA4 | |
| SCHEMBL9848829 | 0.84 | CA12 (0.42) | CA12CA2CA9CA1CA4 | |
| SCHEMBL30218281 | 0.83 | CA12 (0.39) | CA12CA2CA9CA1CA4 | |
| SCHEMBL11701964 | 0.80 | SLC40A1 (0.40) | CA12CA2CA9CA1CA4 | |
| SCHEMBL7973834 | 0.80 | SLC40A1 (0.40) | CA12CA2CA9CA1CA4 | |
| Cinnamic Acid SCHEMBL3807619 | 0.78 | HDAC3 (0.41) | KMT2AKDM4ELMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-06 | — | — | US | disclosed |
| CN-116421567-B | Stable freeze-dried preparation and preparation method and application thereof | 浙江萃泽医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | disclosed |
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-114796133-B | Injection pharmaceutical preparation and preparation method thereof | 浙江萃泽医药科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-0412014-A1 | Benzothiazine derivatives, their preparation and their uses as medicines or as intermediates for the synthesis of medicines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-02-06 | — | — | EP | disclosed |
| WO-1989003682-A1 | BENZOTHIAZINE DIOXIDE DERIVATIVES | PFIZER INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| CN-86103603-A | The preparation method of the derivative of benzothiazine dioxide | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0207622-A2 | Benzothiazine dioxide derivatives | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4614741-A | INJECTABLE SUSPENSIONS | TROPONWERKE GMBH & CO., KG (DE) | 1986-09-30 | — | — | US | disclosed |
| EP-0085866-B1 | DERIVATIVES OF BENZO-1,2-THIAZINE-1,1-DIOXIDE, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CHIESI FARMACEUTICI S.p.A. (IT) | 1986-04-09 | — | — | EP | disclosed |
| US-4581458-A | 5-substituted-3-aminoisoxazole compounds | WARNER-LAMBERT COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| US-4489077-A | 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides | WARNER-LAMBERT COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0123418-A1 | 4-Hydroxy-N-(5((substituted hetero) methyl)-3-isoxazolyl-2H-1,2-benzothiazine-3-carboxamide,1,1-dioxide and 4-hydroxy-2-alkyl-N-(5-((substituted hetero) methyl)-3-isoxazolyl)2H-1,2-benzothiazine-3-carboxamide,1,1-dioxide | WARNER-LAMBERT COMPANY (US) | 1984-10-31 | — | — | EP | disclosed |
| EP-0085866-A1 | Derivatives of benzo-1,2-thiazine-1,1-dioxide, a process for their preparation and pharmaceutical compositions containing the same | CHIESI FARMACEUTICI S.p.A. (IT) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | CA12 2912/4885CA2 2064/4885CA9 2352/4885 |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | CA12 2781/4885CA2 3425/4885CA9 3689/4885 |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | JAK1, TNF, CYP4A11 | CA12 2912/4885CA2 2064/4885CA9 2352/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | CA12 2912/4885CA2 2064/4885CA9 2352/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | CA12 2696/4885CA2 1925/4885CA9 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.